Governance Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:45:05 17/09/2024 BST			5-day change	1st Jan Change
1,145.59 ^USD	-0.65%		+0.42%	+29.92%

09-16	Transcript : Regeneron Pharmaceuticals, Inc. Presents at European Society for Medical Oncology Congress 2024, Sep-16-2024 02:30 PM
09-13	Regeneron, Sanofi Get FDA Nod for Treatment of Chronic Rhinosinusitis With Nasal Polyps	MT

Executive Committee: Regeneron Pharmaceuticals, Inc.

Manager

Positions heldSince

Leonard Schleifer

71 year

Chief Executive Officer	07/01/1988
Founder	07/01/1988
President	07/01/1988

George Yancopoulos

64 year

Chief Tech/Sci/R&D Officer	31/12/2000
Founder	07/01/1988
President	31/12/2000

Mark Volpe

Comptroller/Controller/Auditor

31/12/2011

Patrice Gilooly

Chief Operating Officer

31/12/1997

Bob McCowan

Chief Tech/Sci/R&D Officer

Maya Bermingham

General Counsel

31/12/2014

Andrew Murphy

66 year

Chief Tech/Sci/R&D Officer

31/12/2018

Johnathan Lancaster

Chief Tech/Sci/R&D Officer

31/12/2018

Jason Pitofsky

47 year

Comptroller/Controller/Auditor

04/02/2024

Melissa Lozner

Compliance Officer

31/12/2021

Joseph LaRosa

65 year

General Counsel	05/09/2011
Corporate Secretary	05/09/2011

Neil Stahl

67 year

Chief Tech/Sci/R&D Officer

31/12/2014

Ned Braunstein

General Counsel

31/12/2008

Sally A. Paull

Human Resources Officer

31/12/2015

Christopher Fenimore

53 year

Director of Finance/CFO

04/02/2024

Ryan Crowe

Investor Relations Contact

Composition of the Board of Directors: Regeneron Pharmaceuticals, Inc.

Director

CommitteesSince

George Yancopoulos

64 year

Chairman

08/06/2023

Christine Poon

71 year

Executive Committee	31/08/2006
Finance Committee Chair
Governance Committee
Compensation Committee Chair	15/11/2010
Finance Committee	04/05/2011
Audit Committee
Nominating Committee

David Schenkein

66 year

Governance Committee	30/04/2015
Nominating Committee	30/04/2015
Compensation Committee
Governance Committee Chair
Nominating Committee Chair

Bonnie Bassler

61 year

Governance Committee	11/09/2016
Compensation Committee	29/07/2020
Governance Committee Chair
Nominating Committee Chair

N. Coles

63 year

Executive Committee	17/03/2011
Audit Committee	16/02/2017

Arthur Ryan

81 year

Audit Committee	31/12/2002
Governance Committee Chair	31/12/2002

George Sing

74 year

Compensation Committee	07/01/1988
Audit Committee Chair	07/01/1988

Huda Zoghbi

69 year

Compensation Committee

11/09/2016

Joseph Goldstein

83 year

Governance Committee

13/06/2019

Michael Brown

83 year

Governance Committee

31/05/1991

Kathryn Guarini

52 year

Audit Committee

07/09/2023

Craig Thompson

71 year

Director/Board Member	02/10/2022
Independent Dir/Board Member	02/10/2022

Leonard Schleifer

71 year

Chairman

08/06/2023

Latest Appointments: Regeneron Pharmaceuticals, Inc.

BridgeBio Pharma, Inc. Announces Executive Changes	07-23	CI
Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024	01-31	CI
Regeneron Pharmaceuticals, Inc. Appoints Philip Gregory as Senior Vice President and Head of Regeneron Cell Medicines	01-29	CI
Regeneron Pharmaceuticals Chief Financial Officer to Retire in February	11/09/23	MT
Regeneron Pharmaceuticals Finance Chief Robert Landry to Retire; Successor Named	11/09/23	MT
Regeneron says CFO Landry to retire in February	08/09/23	RE
Regeneron Pharmaceuticals, Inc. Announces Retirement of Robert E. Landry, Executive Vice President, Finance, in February 2024	08/09/23	CI

More news

Former Officers and Directors: Regeneron Pharmaceuticals, Inc.

Insider

Positions held

SinceUntil

Robert Landry

Director of Finance/CFO	02/10/2013	04/02/2024
Corporate Officer/Principal	08/09/2013	02/10/2013

Marc Tessier-Lavigne

Director/Board Member	20/11/2011	31/08/2023
Independent Dir/Board Member	20/11/2011	31/08/2023

David Weinreich

Private Equity Investor

31/01/2016

31/07/2023

P. Vagelos

Chairman

31/12/1994

08/06/2023

Harold Brakewood

Corporate Officer/Principal

30/11/2015

30/11/2021

James Cassidy

Corporate Officer/Principal

31/01/2020

31/07/2021

Neil Graham

Corporate Officer/Principal

31/12/2008

31/12/2019

Jay Markowitz

Corporate Officer/Principal

04/01/2017

31/12/2019

Ke Andrew Yuan

Corporate Officer/Principal

31/12/2014

31/12/2018

Manisha A. Narasimhan

Investor Relations Contact

31/08/2011

31/10/2018

Aaron Ondrey

Corporate Officer/Principal

28/02/2010

31/10/2018

Phillip Gutry

Corporate Officer/Principal

31/05/2015

30/09/2018

Jesper Gromada

Corporate Officer/Principal

30/06/2012

30/09/2018

Charles A. Baker

Director/Board Member	31/01/1989	07/06/2018
Independent Dir/Board Member	31/01/1989	07/06/2018

Robert J. Terifay

Corporate Officer/Principal

25/02/2007

04/01/2018

Peter Powchik

Corporate Officer/Principal

30/09/2006

31/12/2017

Catherine Stehman-Breen

General Counsel

31/12/2014

28/02/2017

Pamela A. Trail

Corporate Officer/Principal

31/07/2010

28/02/2017

William J. Sasiela

Corporate Officer/Principal

31/12/2009

31/12/2016

Douglas S. McCorkle

Comptroller/Controller/Auditor

30/04/1998

30/12/2016

Kevin Bailey

Private Equity Investor

01/10/1991

31/12/2015

Robert Alexander Ingram

Director/Board Member	03/04/2014	09/11/2015
Independent Dir/Board Member	10/03/2015	09/11/2015

Murray Goldberg

Chief Administrative Officer	28/02/1995	30/03/2015
Director of Finance/CFO	28/02/1995	02/10/2013
Treasurer	28/02/1995	07/05/2013

Eric M. Shooter

Director/Board Member	07/01/1988	29/01/2014
Founder	07/01/1988	29/01/2014
Independent Dir/Board Member	07/01/1988	29/01/2014
Corporate Officer/Principal	07/01/1988	01/09/2009

Hala Mirza

Public Communications Contact

31/12/2013

Julie Clark

Corporate Officer/Principal

30/04/2011

30/09/2012

Carrie Brownstein

Corporate Officer/Principal

31/07/2012

Jim Tripp

Director/Board Member

31/12/2006

31/12/2011

Daniel Brims

Corporate Officer/Principal

30/07/2011

Stuart A. Kolinski

General Counsel	31/08/2000	-
Corporate Secretary	31/08/2000	-

Michael Aberman

Investor Relations Contact

22/03/2010

Randall G. Rupp

Corporate Officer/Principal

30/06/1991

01/04/2008

Imogene Dunn

Corporate Officer/Principal

31/12/2002

31/12/2007

Beth Levine

Compliance Officer	31/12/2007	31/08/2022
Corporate Officer/Principal	31/12/2007	-

Alain Thibault

Chief Tech/Sci/R&D Officer	01/09/2009	13/12/2011
Corporate Officer/Principal	25/02/2007	01/09/2009

Michael E. Faerm

Corporate Officer/Principal

30/09/2004

Merdad Parsey

Chief Tech/Sci/R&D Officer

31/12/2001

31/12/2003

Kremena Simitchieva

Sales & Marketing

31/12/2003

Hao Zhou

Chief Tech/Sci/R&D Officer

30/12/2001

Fred Middleton

Director/Board Member	31/12/1987	31/12/2000
Director of Finance/CFO	31/12/1987	31/12/2000

William G. Roberts

Chief Tech/Sci/R&D Officer	30/04/1999	-
General Counsel	30/04/1999	-

Denny Lanfear

Corporate Officer/Principal

31/12/1990

31/12/1998

Prasad Inampudi

Corporate Officer/Principal

30/12/1998

Hans-Peter Guler

Corporate Officer/Principal

31/03/1998

Ronald M. Lindsay

Corporate Officer/Principal

31/12/1996

Peter S. DiStefano

Corporate Officer/Principal

31/12/1990

31/12/1996

Christopher Chapman

Chief Tech/Sci/R&D Officer

31/12/1991

31/12/1993

Stephen P. Squinto

Corporate Officer/Principal

31/12/1988

31/12/1991

Alfred G. Gilman

Director/Board Member	07/01/1988	-
Founder	07/01/1988	-
Independent Dir/Board Member	07/01/1988	-
Corporate Officer/Principal	07/01/1988	01/09/2009

Brendan Classon

Corporate Officer/Principal

Robert Lisicki

Corporate Officer/Principal

Carrie Murray

Corporate Officer/Principal

Joseph Ricculli

Public Communications Contact

Gene Zhu

Corporate Officer/Principal

Marcella Ruddy

Corporate Officer/Principal

Justin Holko

Investor Relations Contact

Alexandra Bowie

Public Communications Contact

Eric S. Furfine

Corporate Officer/Principal

Arleen Goldenberg

Public Communications Contact

Peter G. Dworkin

Public Communications Contact

14/12/2009

Paul F. Lubetkin

General Counsel	-	-
Corporate Secretary	-	-

Fredric D. Price

Chief Administrative Officer	-	-
Director of Finance/CFO	-	-

Joseph Pantginis

Corporate Officer/Principal

Catharine E. Johnson

Corporate Officer/Principal

Matt I. Hermann

Corporate Officer/Principal

Weng Tao

Corporate Officer/Principal

Charles Poole

Public Communications Contact

Sondra Smyrnios

Corporate Officer/Principal

Potoula Gjidija

Public Communications Contact

Paul Lin

Corporate Officer/Principal

Christian Rommel

Chief Tech/Sci/R&D Officer	-	-
Corporate Officer/Principal	-	-

Steven E. Buchholz

Corporate Officer/Principal

Sean Stevens

Corporate Officer/Principal

Terence E. Ryan

Corporate Officer/Principal

Avner Ingerman

Corporate Officer/Principal

Janet van Adelsberg

Corporate Officer/Principal

Greg DiPasquale

Corporate Officer/Principal

Elizabeth Floegel

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	29
Female	7

Of which Executive Committee

Male	12
Female	4

Of which Directors

Male	12
Female	1

ESG Refinitiv

B+

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Employees

13,926

Sector

Biotechnology & Medical Research

Calendar

19/09/2024 - Euretina Congress - Jean-Francois Korobelnik, MD

More about the company

Departures of Key Persons

P. Vagelos

Chairman

31/12/1994 08/06/2023

Governance Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Executive Committee: Regeneron Pharmaceuticals, Inc.

Composition of the Board of Directors: Regeneron Pharmaceuticals, Inc.

Latest Appointments: Regeneron Pharmaceuticals, Inc.

Former Officers and Directors: Regeneron Pharmaceuticals, Inc.

Age distribution of managers

Parity Men Women

Environment

Governance

Controversy

Company Profile

Departures of Key Persons

Governance Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Executive Committee: Regeneron Pharmaceuticals, Inc.

Composition of the Board of Directors: Regeneron Pharmaceuticals, Inc.

Latest Appointments: Regeneron Pharmaceuticals, Inc.

Former Officers and Directors: Regeneron Pharmaceuticals, Inc.

Age distribution of managers

Parity Men Women

Environment

Social

Governance

Controversy

Company Profile

Departures of Key Persons